Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Breckenridge Pharmaceutical, Inc

Breckenridge Pharmaceutical, Inc Recalls

All product recalls associated with Breckenridge Pharmaceutical, Inc.

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

304

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 801–820 of 4747 recalls

Alprazolam Tablets (Breckenridge) – CGMP Contamination Risk (2023)

CGMP Deviations: Potential risk of Cross Contamination

Class IIModerate

FDAMar 2, 2023Nationwide• Breckenridge Pharmaceutical, Inc

Heparin Sodium Injection (Sagent) – Labeling Issue (2023)

Labeling: Not elsewhere classified

Class IIModerate

FDAFeb 28, 2023Nationwide• Sagent Pharmaceuticals Inc

Nose Better Gel (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

1...39 404142 43...238

Page 41 of 238Next

FDA

Feb 24, 2023

Nationwide

• Ecometics, Inc.

Colchicine Tablets (Zydus) – Impurity Specification Failure (2023)

Failed Impurities/Degradation Specifications: An out-of-specification (OOS) result was observed during release testing of one lot for a related substance, i.e. Beta-lumicolchicine.

Class IIILow

FDAFeb 24, 2023AZ, MS, OH• Zydus Pharmaceuticals (USA) Inc

Fentanyl Injection (SCA Pharmaceuticals) – Subpotent Drug (2023)

Subpotent Drug

Class IIILow

FDAFeb 24, 2023Nationwide• SCA Pharmaceuticals

Unguentine Maximum Strength (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

FDAFeb 24, 2023Nationwide• Ecometics, Inc.

Alcolado Relampago (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

FDAFeb 24, 2023Nationwide• Ecometics, Inc.

Activator Concentrate (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

FDAFeb 24, 2023Nationwide• Ecometics, Inc.

Soltice Quick-RUB (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

FDAFeb 24, 2023Nationwide• Ecometics, Inc.

Vencedor Medicated Balm (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

FDAFeb 24, 2023Nationwide• Ecometics, Inc.

Unguentine Burn Ointment (Ecometics) – CGMP Deviation (2023)

CGMP DEVIATIONS

Class IIModerate

FDAFeb 24, 2023Nationwide• Ecometics, Inc.

NaturalCare Allergy Drops (Nutraceutical) – raw material discoloration (2023)

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Class IIModerate

FDAFeb 23, 2023Nationwide• Nutraceutical Corporation

Clear Eyes Allergy Relief (Teva) – impurity specification failure (2023)

Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Class IIModerate

FDAFeb 23, 2023Nationwide• Teva Pharmaceuticals USA Inc

Tempus Pro Patient Monitor (Remote Diagnostic) - Safety Issues (2023)

During internal testing, Regulatory Compliance issues were identified regarding the Monitor and Power Supplies for fluid ingress and basic safety issues.

FDAFeb 23, 2023Nationwide• Remote Diagnostic Technologies Ltd. Farnborough Aerospace Centre Aerospace Boulevard Farnborough United Kingdom

bioAllers Mold Drops (Nutraceutical) – Material Discoloration (2023)

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Class IIModerate

FDAFeb 23, 2023Nationwide• Nutraceutical Corporation

Cold & Sinus Nasal Spray (Nutraceutical) – Material Discoloration (2023)

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Class IIModerate

FDAFeb 23, 2023Nationwide• Nutraceutical Corporation

bioAllers Nasal Spray (Nutraceutical) – Material Discoloration (2023)

CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Class IIModerate

FDAFeb 23, 2023Nationwide• Nutraceutical Corporation

Metformin Extended-Release (Teva) – NDMA contamination (2023)

CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Class IIModerate

FDAFeb 22, 2023CA• Teva Pharmaceuticals USA Inc

Gabapentin Tablets (Sciegen) – tablet mix-up (2023)

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Class IIILow

FDAFeb 17, 2023Nationwide• Sciegen Pharmaceuticals Inc

Testosterone Cypionate Injection (Azurity) – Crystal Redissolution Issue (2023)

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Class IIModerate

FDAFeb 15, 2023Nationwide• Azurity Pharmaceuticals, Inc.